Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report issued on Saturday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 target price on the stock.

Lipocine Stock Up 2.0 %

Shares of LPCN opened at $4.54 on Friday. Lipocine has a 12-month low of $2.38 and a 12-month high of $11.79. The firm has a market capitalization of $24.29 million, a PE ratio of -5.97 and a beta of 1.18. The stock’s fifty day simple moving average is $5.08 and its 200-day simple moving average is $5.62.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. Analysts anticipate that Lipocine will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission (SEC). 9.11% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.